CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hikma Pharmaceuticals Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hikma Pharmaceuticals Plc
1 New Burlington Place
Phone: +44 2073992760p:+44 2073992760 LONDON, W1S 2HR  United Kingdom Ticker: HIKHIK
Business Summary
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes-Yes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Said S.Darwazah 66 9/1/2023 7/1/2007
Chief Executive Officer, Executive Director RiadMishlawi 9/1/2023 1/1/2011
Executive Vice Chairman of the Board, President of MENA Mazen S.Darwazah 1/1/2018 9/8/2005
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Arab Pharmaceutical Manufacturing Co Ltd P.O. Box 1695 Amman Jordan
Ste Promotion Pharmaceutique du Mghrb SA Rue 7. zone industrielle du Sahel HAD SOUALEM Morocco
Hikma Italia S.P.A Viale Certosa, 10 Pavia Italy
7 additional Subsidiary records available in full report.

Business Names
Business Name
Al Jazeera Pharmaceutical Industries Ltd.
AMKI MENA Holdings
Arab Pharmaceutical Manufacturing Co Ltd
27 additional Business Names available in full report.

General Information
Number of Employees: 8,967 (As of 12/31/2023)
Outstanding Shares: 221,081,371 (As of 6/30/2024)
Shareholders: 693
Stock Exchange: LON
Federal Tax Id: 223114571
Fax Number: +44 2073992761


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024